Clinical Trial Update: A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacokinetics of escalating doses of AGS67E as monotherapy in subjects with relapsed or refractory lymphoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Malignancies

Drugs mentioned

• AGS67E

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Relapsed Lymphoid Malignancy, Refractory Lymphoid Malignancy | Phase 1 | Status: COMPLETED